EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [41] A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
    Malorni, Luca
    Curigliano, Giuseppe
    Minisini, Alessandro Marco
    Cinieri, Saverio
    Tondini, Carlo
    Arpino, Grazia
    Pavesi, Lorenzo
    Martignetti, Angelo
    Criscitiello, Carmen
    Puglisi, Fabio
    Pestrin, Marta
    Sanna, Giuseppina
    Moretti, Erica
    Risi, Emanuela
    Biagioni, Chiara
    Boni, Luca
    Baldari, Daniela
    Buyse, Marc E.
    Biganzoli, Laura
    Di Leo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2-advanced/metastatic breast cancer: updated systematic review
    Harbeck, Nadia
    Brufsky, Adam
    Rose, Chloe Grace
    Korytowsky, Beata
    Chen, Connie
    Tantakoun, Krista
    Jazexhi, Endri
    Nguyen, Do Hoang Vien
    Bartlett, Meaghan
    Samjoo, Imtiaz A.
    Pluard, Timothy
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [43] Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2-metastatic breast cancer: Results from the PACE phase II study
    Serafini, Mara Serena
    Reduzzi, Carolina
    Gerratana, Lorenzo
    Jeselsohn, Rinath
    Mahtani, Reshma L.
    Ma, Cynthia X.
    DeMichele, Angela
    Meisel, Jane Lowe
    Miller, Kathy D.
    Abdou, Yara
    Riley, Elizabeth C.
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Burstein, Harold J.
    Tolaney, Sara M.
    DeMeo, Michelle K.
    Liu, Yuan
    Gauthier, Eric
    Ren, Yue
    Regan, Meredith M.
    Liu, Huiping
    Mayer, Erica L.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2024, 84 (06)
  • [44] EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
    Aftimos, Philippe
    Bardia, Aditya
    Kaklamani, Virginia G.
    Lu, Janice
    Bihani, Teeru
    Jung, JungAh
    Anderson-Villaluz, Alfred T.
    Conlan, Maureen G.
    Cortes, Javier
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC): results from the phase I TAKTIC trial
    Wander, Seth A.
    Keenan, Jennifer C.
    Niemierko, Andrzej
    Juric, Dejan
    Spring, Laura M.
    Supko, Jeffrey
    Vidula, Neelima
    Isakoff, Steven J.
    Ryan, Lianne
    Padden, Sarah
    Fisher, Elizabeth
    Newton, Amber
    Moy, Beverly
    Ellisen, Leif
    Micalizzi, Douglas S.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (05)
  • [46] Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2-breast cancer (LEADER).
    Spring, Laura
    Griffin, Colleen
    Isakoff, Steven J.
    Moy, Beverly
    Wander, Seth Andrew
    Shin, Jennifer
    Abraham, Elizabeth
    Habin, Karleen
    Patel, Jaymin M.
    Comander, Amy H.
    Mulvey, Therese Marie
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER plus MBC): The Guy's Cancer Centre Experience
    Gousis, C.
    Michoglou, K.
    Lowe, H.
    Kapiris, M.
    Angelis, V.
    CLINICAL ONCOLOGY, 2022, 34 (04) : E178 - E178
  • [48] A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
    Beeram, M.
    Tolaney, S. M.
    Beck, J. T.
    Dickler, M. N.
    Conlin, A. K.
    Dees, C.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Kambhampati, S. R. P.
    Costigan, T. M.
    Chan, E.
    Pant, S.
    Kalinsky, K.
    Burris, H. A.
    Becerra, C. H.
    Rexer, B. N.
    Puhalla, S. L.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
    von Arx, C.
    Calabrese, A.
    Martinelli, C.
    Di Lauro, V.
    Grimaldi, V.
    Pensabene, M.
    Caputo, R.
    Cerillo, I.
    Cianniello, D.
    Buono, G.
    Verrazzo, A.
    Pacilio, C.
    Di Rella, F.
    Nuzzo, F.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [50] Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a posttreatment multiomic signature for patients with ER+/HER2-metastatic breast cancer (SIDEOUT-3)
    Abu-Khalaf, Mm
    Pierobon, M.
    Denduluri, N.
    Valdes-Albini, F.
    Forero-Torres, A.
    Clark, A.
    Yung, R.
    Mita, M.
    Christensen, S.
    Awerkamp, K.
    Dunetz, B.
    Murphy, R.
    Hatzis, C.
    Zelterman, D.
    Liotta, L.
    Petricoin, E.
    CANCER RESEARCH, 2019, 79 (04)
12345